Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 8/20 | 0.33 |
| ▸ | DRD3 | P35462 | 8/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | CPT1A | P50416 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897662 | 0.87 | GRM5 (0.55) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL2897665 | 0.87 | GRM5 (0.55) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL3974922 | 0.87 | GRM5 (0.40) | GRM5MDM2PIK3C3KCNH2 | |
| SCHEMBL4085913 | 0.86 | SCD (0.42) | GRM5MDM2DRD2DRD3PIK3C3 | |
| SCHEMBL2890599 | 0.86 | GRM5 (0.46) | GRM5DRD2DRD3PIK3C3CPT1A | |
| SCHEMBL2890593 | 0.86 | GRM5 (0.46) | GRM5DRD2DRD3PIK3C3CPT1A | |
| SCHEMBL2899231 | 0.84 | GRM5 (0.41) | GRM5DRD2DRD3PIK3C3KCNH2 | |
| SCHEMBL2899224 | 0.84 | GRM5 (0.41) | GRM5DRD2DRD3PIK3C3KCNH2 | |
| SCHEMBL2896453 | 0.84 | GRM5 (0.44) | GRM5DRD2DRD3KCNH2HCRTR1 | |
| SCHEMBL2896447 | 0.84 | GRM5 (0.44) | GRM5DRD2DRD3KCNH2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| WO-2009054793-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885MDM2 4831/4885DRD2 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.